Literature DB >> 32298188

How can biosimilars change the trajectory of breast cancer therapy?

Dario Trapani1,2, Giuseppe Curigliano1,2.   

Abstract

Entities:  

Keywords:  Biosimilars; SBP; UHC; breast cancer; cancer policy; similar biotherapeutic products; trastuzumab

Mesh：

Substances：

Year:  2020        PMID： 32298188     DOI： 10.1080/14737140.2020.1757438

Source DB:  PubMed          Journal:  Expert Rev Anticancer Ther        ISSN： 1473-7140            Impact factor:   4.512


× No keyword cloud information.
  3 in total

1.  Quantifying geographical accessibility to cancer clinical trials in different income landscapes.

Authors:  G Tini; D Trapani; B A Duso; P Beria; G Curigliano; P G Pelicci; L Mazzarella
Journal:  ESMO Open       Date:  2022-06-21

Review 2.  Implications of Oncology Trial Design and Uncertainties in Efficacy-Safety Data on Health Technology Assessments.

Authors:  Dario Trapani; Kiu Tay-Teo; Megan E Tesch; Felipe Roitberg; Manju Sengar; Sara C Altuna; Michael J Hassett; Armando A Genazzani; Aaron S Kesselheim; Giuseppe Curigliano
Journal:  Curr Oncol       Date:  2022-08-16       Impact factor: 3.109

3.  Uptake of Trastuzumab Biosimilars for the Treatment of HER2-Positive Breast Cancer: A Real-World Experience from a Cancer Center.

Authors:  Michela Piezzo; Roberta D'Aniello; Ilaria Avallone; Bruno Barba; Daniela Cianniello; Stefania Cocco; Antonio D'Avino; Germira Di Gioia; Vincenzo Di Lauro; Giuseppina Fusco; Raffaele Piscitelli; Claudia von Arx; Michelino De Laurentiis; Piera Maiolino
Journal:  Pharmaceutics       Date:  2021-05-10       Impact factor: 6.321
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.